Susan G. Komen®, the world’s leading breast cancer organization, applauds the introduction of the Breast Cancer Research Stamp Reauthorization Act of 2026 and urges swift passage to secure continued vital research funds. The legislation, introduced by Senator Jacky Rosen (D-NV), Senator Ashley Moody (R-FL), Representative Beth Van Duyne (R-TX-24) and Representative Debbie Wasserman Schultz (D-FL-25), would allow the continuation of an important source for breast cancer research funds.
“For almost three decades, the Breast Cancer Research Stamp has raised nearly $100 million for breast cancer research—research that has led to significant progress in the detection and treatment of a disease that is estimated to take the lives of nearly 43,000 Americans in 2026 alone,” said Molly Guthrie, vice president of policy and advocacy at Susan G. Komen. “The reauthorization of this stamp will allow for yet another decade’s worth of investment in critical scientific discovery that will save lives.”
In the United States, breast cancer affects 1 in 8 women and 1 in 1,000 men over their lifetime with about one life lost every 12 minutes. The Breast Cancer Research Stamp is a special “semi-postal” stamp, which are sold at a small surcharge to fund causes determined to be in the national interest—such as breast cancer research. It allows consumers to support breast cancer research in a convenient way by paying a little more than regular first-class postage with proceeds of the surcharge going toward essential breast cancer research at the National institutes of Health and the Department of Defense’s Breast Cancer Research Program.
The stamp is a public-private partnership that generates private dollars to further the impact of public investment in biomedical research. Breast cancer research projects funded by the stamp since 2000 include: research on environmental exposures, pregnancy-associated breast cancer, predictions of metastatic disease, identification of predictive biomarkers for response of tumors to current therapies and more. There have been hundreds of articles and dozens of patents deriving from these projects advancing our understanding of this disease.
Thanks to breakthroughs in cancer research, more patients today are surviving this deadly disease, but there is still much progress needed to actualize a world without deaths from breast cancer. Authorization for this important funding mechanism is set to expire at the end of 2027. The Breast Cancer Research Stamp Reauthorization Act of 2026 would reauthorize the Breast Cancer Research Stamp for another ten years—driving vital breakthroughs through 2037.
“This bipartisan legislation represents a critical opportunity to sustain a proven, innovative funding mechanism that has advanced lifesaving breast cancer research for nearly three decades,” said Guthrie. “We applaud the leadership of Senators Rosen and Moody and Congresswomen Van Duyne and Wasserman-Schultz in introducing legislation to reauthorize the Breast Cancer Research Stamp and urge Congress to swiftly act. Every dollar raised through the Breast Cancer Research Stamp can help advance needed discoveries and save more lives.”
About Susan G. Komen®
Susan G. Komen® is the world’s leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow’s cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at www.komen.org/contact-us/follow-us/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260416580260/en/
Media gallery
